Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Legal & General Group Plc acquired 135,434 shares of Supernus Pharmaceuticals in the second quarter, valued at approximately $6.3 million and representing about 0.23% of the company.
• Supernus reported quarterly revenue of $219.1 million, up 32.4% year over year and above estimates, but posted an EPS loss of $1.01 versus expectations for $0.42 in earnings.
• SUPN shares opened at $44.03, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $62.83.

Legal & General Group Plc acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 135,434 shares of the specialty pharmaceutical company's stock, valued at approximately $6,299,000. Legal & General Group Plc owned approximately 0.23% of Supernus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sit Investment Associates Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company's stock worth $3,240,000 after acquiring an additional 250 shares during the period. Summit Global Investments raised its stake in shares of Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company's stock valued at $229,000 after purchasing an additional 256 shares during the period. Maryland State Retirement & Pension System lifted its holdings in Supernus Pharmaceuticals by 3.6% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company's stock worth $415,000 after purchasing an additional 290 shares in the last quarter. SummitTX Capital L.P. boosted its stake in Supernus Pharmaceuticals by 2.7% in the 4th quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company's stock worth $580,000 after purchasing an additional 303 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in shares of Supernus Pharmaceuticals by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company's stock valued at $752,000 after buying an additional 321 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $44.03 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $42.45 and a 1-year high of $59.68. The company has a market capitalization of $2.56 billion, a P/E ratio of -22.93, a P/E/G ratio of 0.81 and a beta of 0.56. The firm's 50 day simple moving average is $46.77 and its 200 day simple moving average is $48.49.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.Supernus Pharmaceuticals's quarterly revenue was up 32.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.40 EPS. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SUPN. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source